|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
MGD |
|
|
|
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The PTEN gene, located on 10q23, has recently been implicated as a candidate tumor suppressor gene in brain, breast and prostate tumors.
|
9331072 |
1997 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
|
9371490 |
1997 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
One somatic mutation (17%), a 1 bp deletion, was detected in exon 7 of the gene, in one tumor, indicating that somatic mutations of the PTEN gene may occur in primary prostate tumors.
|
9671408 |
1998 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Based on the identification of mutations in sporadic breast, brain and prostate tumours, we decided to examine the potential role of PTEN in sporadic malignant melanoma.
|
9764804 |
1998 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
To further define the role of PTEN/MMAC1 in the development of prostate cancer and its spectrum of genetic alterations, we analysed 40 pT2 or pT3 prostate tumors for allelic loss, mutations, and homozygous deletions using PCR-based methods.
|
9788441 |
1998 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Finally, higher levels of Akt activation are observed in human prostate cancer cell lines and xenografts lacking PTEN/MMAC1 expression when compared with PTEN/MMAC1-positive prostate tumors or normal prostate tissue.
|
9861013 |
1998 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer.
|
12168088 |
2002 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Downregulation of PTEN/MMAC/TEP1 expression in human prostate cancer cell line DU145 by growth stimuli.
|
12190124 |
2002 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival.
|
12429629 |
2002 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells.
|
15205473 |
2004 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
|
15492994 |
2004 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Metastatic properties of prostate cancer cells are controlled by VEGF.
|
15500293 |
2005 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis.
|
15897909 |
2005 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer.
|
16421604 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation.
|
16432235 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Significantly reduced PTEN expression was observed in AI versus benign and hormone naïve prostate tumors.
|
16496415 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Significantly reduced PTEN expression was observed in AI versus benign and hormone naïve prostate tumors.
|
16496415 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is lost as a function of prostate tumor androgen dependence.
|
16637073 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Expression of mTOR signaling pathway markers in prostate cancer progression.
|
16652388 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.
|
16697957 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Integrative molecular concept modeling of prostate cancer progression.
|
17173048 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
The role of PTEN in prostate cancer cell tropism to the bone micro-environment.
|
17347137 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.
|
17372210 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
PosttranslationalModification
|
group |
LHGDN |
Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation.
|
17606718 |
2007 |